Rangaswamy Govindarajan
Professor
faculty
Internal Med, College of Medicine
Research Areas
Biography and Research Information
OverviewAI-generated summary
Rangaswamy Govindarajan's research focuses on the clinical and translational aspects of gastrointestinal cancers, sarcoma, and melanoma. He investigates novel therapeutic strategies, including oncolytic viruses and immune checkpoint blockade, to enhance immune responses and improve survival rates in patients with hepatocellular carcinoma and pancreatic cancer. His work also explores the reprogramming of the tumor microenvironment to overcome resistance to immunotherapy.
Dr. Govindarajan's research extends to understanding the quality of life and psychological well-being of patients newly diagnosed with advanced cancer. He has conducted preliminary efficacy trials for interventions such as self-affirmation and has examined the spiritual well-being of cancer patients. His publications address innovative approaches to clinical trial implementation and the subgroup analysis of quality-of-life outcomes.
With an h-index of 14 and 66 total publications, Dr. Govindarajan is an active contributor to the field. He leads a research group at the University of Arkansas for Medical Sciences (UAMS) and collaborates with researchers within the institution, including Rang Govindarajan, Bahaa Mustafa, Steven R. Post, and Martin J. Cannon.
Research Overview
Dr. Rangaswamy Govindarajan is a hematologist and medical oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS). He is also a Professor in the UAMS Department of Internal Medicine, Division of Hematology/Oncology.Dr. Govindarajan received his medical degree from Mysore Medical College at the University of Mysore in Mysore, India. He completed an internship in General Medicine, Surgery and Ob/GYN/Pediatrics at K.R. Hospital & Cheluvamba Hospital in Mysore, India. Dr. Govindarajan completed his medical training at UAMS, first with a residency in Internal Medicine and then, as a fellow in the Division of Hematology/Oncology. He is board certified in Internal Medicine, Hematology and Oncology and is a Diplomate of the American Board of Internal Medicine.Dr. Govindarajan is a member of the American Society of Hematology and the American Society of Clinical Oncology. His primary clinical and research interests are gastrointestinal cancers, sarcoma and melanoma.
Metrics
- h-index: 14
- Publications: 67
- Citations: 1,520
Selected Publications
-
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study (2026)
-
Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer (2025)
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025)
-
Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC). (2025)
-
Incidence and impact of incidental pulmonary embolism in solid cancer patients. (2025)
-
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)
-
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors (2024)
-
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27). (2023)
Grants & Funding
- CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etopos NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B Principal Investigator
- A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combinatio Sanofi-Aventis Principal Investigator
- CTSU ECOG 2108, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cance NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group Principal Investigator
- UARK 2004-40: A Companion Protocol for Biomarker Development and Pharmacogenetic Analysis in Subjects Enrolled in Clinical Therapeutic Trials Using Pa Amgen, Inc. Principal Investigator
- A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bo Merck & Company, Inc. Principal Investigator
- RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TR NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B Principal Investigator
- No FP attached NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group Principal Investigator
- Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (CALGB 80803) NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics